Abstract:Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced treatment compliance. Intravenous (IV) iron formulations are increasingly safer, but there is still a risk of infusion and hypersensitivity reactions and the need for a venous access and infusion monitoring. Sucrosomial® iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI unique structural, physicochemical and pharmacokinetic characteristics, together with high iron bioavailability and excellent gastrointestinal tolerance. The analysis of available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and better tolerated than oral iron salts. SI has also demonstrated similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a most valuable first option for treating ID, even more for subjects with intolerance to or inefficacy of iron salts. Moreover, SI should be also considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations.

What problem does this paper attempt to address?

This paper attempts to solve several key problems in the treatment of iron deficiency (ID): 1. **Gastrointestinal side effects of oral iron salts**: As many as 50% of patients experience gastrointestinal side effects when using traditional oral iron salt supplements, which leads to a decrease in treatment compliance. Therefore, a new oral iron preparation is needed that can reduce these side effects and improve patients' treatment compliance. 2. **Risks and limitations of intravenous iron preparations**: Although the safety of intravenous iron preparations has been continuously improved, there are still risks of infusion reactions and allergic reactions, and intravenous access and infusion monitoring are required. In addition, the cost of intravenous iron preparations is also relatively high. Therefore, finding an oral iron preparation that can replace intravenous iron preparations has become an important research direction. 3. **Improving the bioavailability of iron**: Traditional oral iron salt supplements require a relatively high dose to achieve a therapeutic effect due to their low absorption rate, which further increases the risk of gastrointestinal side effects. Therefore, developing an oral iron preparation with higher bioavailability can achieve effective iron supplementation at a lower dose while reducing side effects. To address the above problems, this paper introduces **Sucrosomial® Iron (SI)**, an innovative oral iron preparation with the following main characteristics: - **Structure and composition**: The ferric pyrophosphate in SI is protected by a phospholipid bilayer membrane (mainly from sunflower lecithin) and a sucrosome matrix. This structure enables SI to be absorbed through the paracellular and transcellular pathways (including M cells), thereby increasing the bioavailability of iron and reducing gastrointestinal side effects. - **High bioavailability**: In vitro experiments and animal studies have shown that the iron accumulation in SI is significantly higher than that in traditional oral iron salts, such as ferrous sulfate. In addition, SI can effectively increase hemoglobin and ferritin levels in vivo, showing good bioavailability. - **Excellent gastrointestinal tolerance**: Due to the special structure of SI, iron is gradually released after entering the small intestine, reducing the direct toxic effect on the gastrointestinal tract, thereby improving patients' tolerance. - **Wide range of applications**: SI is not only suitable for general iron - deficiency patients, but also for patient groups that usually require intravenous iron treatment, such as patients with chronic kidney disease, cancer, and after bariatric surgery. For these patients, SI shows efficacy comparable to that of intravenous iron, but with lower risks. In summary, by introducing and evaluating the characteristics and advantages of Sucrosomial® Iron (SI), this paper aims to provide a more effective, safer, and more acceptable treatment plan for iron deficiency.

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment

Supplementation with Sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice

Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study

Sucrosomial® iron absorption studied by in vitro and ex-vivo models

A Randomized, Controlled, Open Label Non-Inferiority Trial of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Patients with Iron Deficiency Anemia in China.

Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non‐randomized, open‐label, proof‐of‐concept study

Oral iron supplementation: new formulations, old questions

Physicochemical and toxicological characterization of a new generic iron sucrose preparation

Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD

Pilot Study to Gain First Indications for the Impact of a 3-Month's Oral Intake of a Sucrosomial Iron Supplement on Hemoglobin in Iron-Deficient Blood Donors

Intravenous iron sucrose in maintenance hemodialysis patients: a prospective randomized controlled multi-center clinical trial

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization

Real-world experience of intravenous iron sucrose supplementation and dynamics of soluble transferrin receptor and hepcidin in a Spanish cohort of absolute iron deficient patients

Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator

Comparative Evaluation of Intestinal Absorption and Functional Value of Iron Dietary Supplements and Drug with Different Delivery Systems

Oral iron therapy: Current concepts and future prospects for improving efficacy and outcomes

Evaluation of Oral Therapy Based on Ferric Sodium EDTA, in Combination With Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate and Selenomethionine, in Iron-Deficiency Anemia: A Real-Life Study

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience

Comparative Evaluation of Sucrosomial Iron and Iron Oxide Nanoparticles as Oral Supplements in Iron Deficiency Anemia in Piglets

The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment